Sezary Syndrome - 21 Studies Found
Terminated |
: Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome :
: 2012-06-19 :
|
Terminated |
: Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome :
: 2005-08-08 : Drug: HuMax-CD4 (zanolimumab) Monoclonal Antibody, 12 weekly infusions. |
Completed |
: Immunization Against Tumor Cells in Sezary Syndrome :
: 2004-12-17 : Biological: Autologous Dendritic Cell Vaccine |
Active, not recruiting |
: Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome :
: 2002-10-03 : Drug: Campath-1H |
Active, not recruiting |
: Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome :
: 2005-09-07 : Drug: alemtuzumab |
Recruiting |
: TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome :
: 2016-06-30 :
|
Recruiting |
: Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) :
|
Completed |
: VircapSeq Virus Detection in Sézary Syndrome :
: 2016-07-15 |
Active, not recruiting |
: Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome :
|
Terminated |
: Temozolomide in Treating Patients With Mycosis Fungoides or Sezary Syndrome : Lymphoma : 1999-12-10 : Drug: temozolomide Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a to |